NCT06336343 - Bimekizumab in Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Plaque Psoriasis

Interventions

DRUG

Bimekizumab

Bimekizumab 320 mg via subcutaneous injections. Bimekizumab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to and neutralizes the biologic functions of both interleukin-17A (IL-17A) and IL-17F, which are known to increase inflammation.

Trial Locations (2)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

08520

RECRUITING

Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey, East Windsor